AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05281510 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAP256V2LS
Description: Administered intravenously
Study NCT05849168 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Participants will complete a 12-week exercise training program. The program consists of 3x/week HIIT sessions on an upright stationary bicycle (\~40 minutes each) and 3x/week home aerobic sessions (any type of aerobic exercise; 45 minutes each).
Study NCT04026503 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Live Long Walk Strong rehabilitation program
Description: Live Long Walk Strong is a rehabilitation program that focuses on impairments known to contribute to mobility decline that are not considered standard of care in rehab and addresses behavioral change within the context of rehabilitation.
Study NCT04026503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Live Long Walk Strong rehabilitation program
Description: Live Long Walk Strong is a rehabilitation program that focuses on impairments known to contribute to mobility decline that are not considered standard of care in rehab and addresses behavioral change within the context of rehabilitation.
Study NCT05473910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC + TSC-100
Description: HA-1 positive
Study NCT05473910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC + TSC-101
Description: HA-2 positive or HA-1 negative
Study NCT05473910 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: SOC alone
Study NCT05155345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Participants will receive subcutaneous (SC) mosunetuzumab on either Day 1 or on Days 1 and 8.
Study NCT05155345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive intravenous (IV) tocilizumab as needed to manage adverse reactions.
Study NCT06029426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMRA-335140
Description: Participants will receive NMRA-335140 at a dose of 80 mg QD, orally
Study NCT06029426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally
Study NCT05421416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: Loratadine is 2nd generation inverse agonist that exerts its effect by targeting H1 histamine receptors.
Study NCT05421416 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sugar pill
Study NCT04887259 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAVA-051
Description: In part 1 and part 2, LAVA-051 will be administered via intravenous (IV) infusion
Study NCT04887259 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin 2
Description: In Part 1 and Part 2, a low dose of interleukin 2 will be given via subcutaneous injection with LAVA-051 in a selected group of patients
Study NCT05323175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine injection
Description: Local anesthesia injected under ultrasound guidance
Study NCT05323175 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care medications
Description: Whatever the ED clinicians normally give for renal colic pain
Study NCT06337188 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental AAC
Description: Participant receives an AAC system comprising 2 wearable sensors for movement-mediated cursor control and muscle activity mediated cursor selection that is integrated with an adaptive and individualized keyboard to test communication performance.
Study NCT06337188 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Generic AAC
Description: Participant receives an AAC system that is similar to that used to satisfy their normal daily communication needs such as an eye-tracking device with a generic AAC keyboard to test communication.
Study NCT05396014 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Self-Care (ESC)
Description: The Enhanced Self-Care intervention will be comprised of educational modules on evidence-based cognitive-behavioral self-management skills for pain. These modules will be provided digitally for self-administration over a period of 12 weeks. There will be no therapist associated with the delivery of these educational materials; however, after the first four modules, email or text messages will be used to make personalized recommendations for accessing additional modules based upon identified problems from the baseline assessment. Additionally, the walking program module will utilize Fitbit step tracking to allow participants to monitor their walking progress.
Study NCT05396014 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy (ACT)
Description: ACT is a form of cognitive behavioral therapy that is well established for the treatment of chronic pain. The goal of ACT is to build psychological flexibility thereby interrupting pain avoidance behavior patterns. Participants randomized to ACT will take part in 12 sessions over the course of 12 weeks. Sessions will be delivered as a combination of 4 remote face-to-face visits with a therapist and 8 therapist-supported online sessions (self-directed online modules supported by provider coaching). Online sessions will focus on helping participants accept pain, connect with negative thoughts and emotions, develop mindfulness and identify and commit to values and goals that are important to them. During face-to-face sessions with the therapist, participants will be encouraged to share their experience of skills practice and mastery, provide examples of skill use at home, and describe what barriers they encountered.
Study NCT05396014 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Evidence-Based Exercise and Manual Therapy (EBEM)
Description: Licensed physical therapists (PTs) or Doctors of Chiropractic (DCs) will rely on evidence-based guidance to direct decision-making on the particular type of manual and exercise therapy that may be best suited to an individual study participant. Special attention will be paid to the clinician's choice of language in regard to the purpose and expected outcomes of manual therapy in order to avoid enhancing catastrophizing ideations or preference for passive interventions. A total of 10 sessions will be provided over an 8-week treatment period. Two sessions per week are provided in the first two weeks followed by weekly sessions over the next 6 weeks. Treatment sessions will last approximately 60 minutes each.
Study NCT05396014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Duloxetine is a serotonin norepinephrine reuptake inhibitor (SNRI) that is FDA-approved for use in Chronic Low-Back Pain, and, as such, is included as a recommended therapy in nearly all current treatment guidelines for low back pain. Study participants will be treated with duloxetine for 12 weeks during the active treatment phase. At the time of randomization, the approved drug pharmacy at each study site will dispense between 185 and 192 duloxetine 30 mg capsules and provide to participants. This will ensure enough capsules to maintain up to a 60 mg dosage through the 12-week intervention phase and to taper the dose in the 13th week if needed.
Study NCT05432765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phenotypic Personalized Medicine Dosing
Description: Phenotypic Personalized Medicine (PPM) will mediate mechanism-independent and patient specific optimization of immunosuppression. We have developed a powerful platform that allows the provider to use clinical data to construct a Parabolic Response Surface (PRS). Using this visualization of the data, the provider can them make a decision on the optimal combination of drug doses needed to achieve the desired outcome.
Study NCT05432765 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Dosing
Description: Providers will decide on the combination of drug doses needed based on their overall assessment per standard of care.
Study NCT05568069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronisation Therapy Defibrillator (CRTD)
Description: An ICD is a device that is implanted under the skin under a local anesthetic. It has a battery/generator component and leads which are fixed into the heart chambers. It has the ability to detect dangerous heart rhythms if they occur, and deliver a shock to treat this to help prevent sudden cardiac death. A CRTD is a pacemaker with a defibrillator function.
Study NCT04312126 — intervention group
Intervention type: DEVICE
Intervention: MRI system
Description: MRI system - GE Discovery MR750 3T
Study NCT04312126 — intervention group
Intervention type: DEVICE
Intervention: MEG system
Description: MEG system The CTF MEG 275 Magnetoencephalography (MEG) scanner system
Study NCT04948866 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ADRD-PC Program
Description: Included in arm/group descriptions
Study NCT04948866 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADRD-PC Program
Description: Included in arm/group descriptions
Study NCT05384171 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Measurement-Based Transition Assistance (MBTA)
Description: Measurement-Based Transition Assistance (MBTA) asks Veterans about their well-being and then provides Veterans with individualized feedback on areas in which they would benefit from additional support with regard to their health, vocational, financial, and social circumstances, along with personalized recommendations for relevant programs, services, and supports.
Study NCT05384171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Measurement-Based Transition Assistance (MBTA)
Description: Measurement-Based Transition Assistance (MBTA) asks Veterans about their well-being and then provides Veterans with individualized feedback on areas in which they would benefit from additional support with regard to their health, vocational, financial, and social circumstances, along with personalized recommendations for relevant programs, services, and supports.
Study NCT06355102 — intervention group
Intervention type: OTHER
Intervention: Conventional treatment and care
Description: Conventional treatment and care
Study NCT05781945 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics
Description: supplementation with Bifidobacterium lactis LA 304, Lactobacillus salivarius LA 302,andLactobacillus acidophilus LA 201+ standard theraph for sars-cov-2
Study NCT05781945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard therapy
Description: standard therapy for sars-cov-2
Study NCT04883645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% Cream
Description: Imiquimod as a 5% cream is being used to treat several skin cancers, including malignant melanoma, basal cell carcinoma (BCC) and SCC. With respect to SCC treatment, it has been demonstrated that imiquimod stimulates tumor destruction by recruiting T cells (cells in the immune system) from blood and by inhibiting tonic anti-inflammatory signals within the tumor. The patient will be instructed to apply imiquimod cream, 7 nights a week for 4 weeks to the oral tumor at bedtime.
Study NCT04739761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: Participants will receive T-DXd administered using an IV bag containing 5% (w/v) dextrose injection infusion solution.
Study NCT04799301 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet with no soda
Description: Weight-maintaining diet without soda, with all carbohydrates originating from sources other than corn and sugar cane
Study NCT04799301 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet with 50% of carb intake from soda
Description: Weight-maintaining diet with 50% of carbohydrates provided as soda, and all other carbohydrates originating from sources other than corn and sugar cane
Study NCT04799301 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet with 20% of carb intake from soda
Description: Weight-maintaining diet with 20% of carbohydrates provided as soda, and all other carbohydrates originating from sources other than corn and sugar cane
Study NCT06293469 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Accelerated Flap Coverage Surgery
Description: Timing of the flap surgery is with a goal of 72 hours from injury
Study NCT06293469 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Flap Timing
Description: Timing of the flap surgery is the standard of care flap timing for the participating institution.
Study NCT05054790 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neo-Bladder Construct
Description: Subjects will undergo an open full thickness bladder biopsy from which autologous urinary bladder smooth muscle and urothelial cells will be procured and expanded ex vivo. After approximately 5 - 7 weeks, expanded cells will be seeded on a biodegradable scaffold to produce the neo-bladder construct that will be surgically implanted onto an opened native bladder during an augmentation cystoplasty.
Study NCT05949801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neucardin
Description: 10 days IV infusion of 0.6 ug/kg/day
Study NCT06141395 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: NGS-based assay for bacterial identification
Description: A total volume of 26ml of whole blood will be sampled from each enrolled patient for three consecutive days. This will be used for Standard-of-Care (SoC) culture and Next Generation Sequencing (NGS), for identification of circulating microorganisms.
Study NCT05949801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 days IV infusion of 0 ug/kg/day
Study NCT05394597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repellent lotion
Description: lotion of the repellent active ingredient IR3535
Study NCT05394597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repellent Wipe
Description: wipe of the repellent active ingredient IR3535
Study NCT05257499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On line debriefing
Description: Online Debriefing in the Simulation Sessions of the Helping Babies Breathe Course
Study NCT05413889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Epic 30-day unplanned readmission risk score
Description: If a patient is identified as having a high risk of readmission defined as readmission risk >20%, a link to transitional and supportive care services (TSC) will be appear in the story board.
Study NCT06244875 — intervention group
Intervention type: OTHER
Intervention: Sampling
Description: Blood and cerebrospinal fluid sampling during the diagnostic visit
Study NCT05783531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VMood
Description: VMood is a digital mental health intervention adapted from an evidence-based in-person intervention. It uses supported self-management approaches, consisting of bibliotherapy (the Antidepressant Skills Workbook) and supportive coaching from a social worker that are provided via the smartphone app. The individual is supported in the use of the skills over the course of three months. The skills in the workbook are grounded in principles of Cognitive Behavioural Therapy.
Study NCT05783531 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced treatment as usual
Description: Participants in the control arm will receive enhanced treatment as usual in the form of usual care from primary care centres and a brief introduction to depression video through the VMood app.
Study NCT06287944 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Actinium Ac 225-DOTA-Daratumumab
Description: Given IV
Study NCT06287944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06287944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow biopsy and aspiration
Study NCT06287944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspiration
Study NCT06287944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06287944 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV
Study NCT06287944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography
Study NCT05413317 — intervention group
Intervention type: OTHER
Intervention: Color Doppler Ultrasound
Description: Comparison with conventional diagnosis strategy including a clinical probability score, D-dimers and chest imaging.
Study NCT06287944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT06287944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo SCT
Study NCT06505369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered by SC injection
Study NCT06505369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered by SC injection
Study NCT06505369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered by oral route
Study NCT06505369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered by oral route
Study NCT06505369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered by SC injection
Study NCT06505369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab will be administered by SC injection
Study NCT05663710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu girentuximab
Description: Given by IV (vein)
Study NCT05743270 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP3
Description: Genetically modified herpes simplex type 1 virus
Study NCT05743270 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CCRT(concurrent chemoradiation therapy)
Description: CCRT consisting of intensity modulated radiation therapy combined with a cis-platinum
Study NCT05663710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given by IV (vein)
Study NCT05663710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given by PO
Study NCT06287944 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Indium In 111-DOTA-Daratumumab
Description: Given IV
Study NCT06287944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT06287944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT06287944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radionuclide Imaging
Description: Undergo nuclear scan
Study NCT05386862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduce THC Use
Description: Reducing THC concentrations and increasing CBD to reduce PTSD symptom severity
Study NCT05894980 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS stimulating left DLPFC
Description: 20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 2 mA) applied to the left DLPFC
Study NCT05894980 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active tDCS stimulating right OFC
Description: 20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 2 mA) applied to the right OFC
Study NCT05894980 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: 20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 0 mA) applied to the left DLPFC
Study NCT06287944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT scan
Study NCT06287944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given sirolimus
Study NCT06287944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given tacrolimus
Study NCT06287944 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Marrow and Lymphoid Irradiation
Description: Undergo TMLI
Study NCT05397041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMB-101
Description: Participants will receive one of several different oral doses of BMB-101 once or twice daily
Study NCT05397041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched Placebo
Study NCT05663710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ArabinoFuranosylGuanine [18F]F-AraG
Description: Given by IV (vein)
Study NCT05224024 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retzius-repairing robot-assisted radical prostatectomy
Description: Repairing the retzius space which is opened during the standard robot assisted radical prostatectomy.